JPY 653.0
(-1.51%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 250.12 Million JPY | 55.85% |
2022 | 160.48 Million JPY | 46.55% |
2021 | 109.5 Million JPY | 21.19% |
2020 | 90.36 Million JPY | 9036000.0% |
2019 | 1000.00 JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 229 Million JPY | -8.44% |
2023 Q4 | 250.12 Million JPY | 39.54% |
2023 Q3 | 179.24 Million JPY | 13.53% |
2023 Q2 | 157.88 Million JPY | 7.04% |
2023 Q1 | 147.5 Million JPY | -8.09% |
2023 FY | 250.12 Million JPY | 55.85% |
2022 Q3 | 153.85 Million JPY | -1.43% |
2022 Q2 | 156.08 Million JPY | 0.0% |
2022 Q4 | 160.48 Million JPY | 4.31% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Shin Nippon Biomedical Laboratories, Ltd. | 42.14 Billion JPY | 99.406% |
Cosmo Bio Company,Limited | 1.84 Billion JPY | 86.458% |
H.U. Group Holdings, Inc. | 152.84 Billion JPY | 99.836% |
FALCO HOLDINGS Co., Ltd. | 10.39 Billion JPY | 97.594% |
BML, Inc. | 40.85 Billion JPY | 99.388% |
Human Metabolome Technologies, Inc. | 656.68 Million JPY | 61.911% |
Precision System Science Co., Ltd. | 2.25 Billion JPY | 88.902% |